EHR4CR Annual Conference November 18-20, 2013 Berlin

Click here to read the full report

 

Report EHR4CR  Annual Conference November 18-20, 2013 Berlin   EHR4Cr annual Conference

Videos
General Information
  • The IMI EHR4CR project runs over 4 years (2011-2014) with a budget of +16 million € and involves 33 partners (academic and industrial)
  • The EHRCR project is -to date- one of the largest public-private partnerships aiming at providing adaptable, reusable and scalable solutions (tools and services) for reusing data from Electronic Health Record systems for Clinical Research.
  • Electronic Health Record (EHR) data offer large opportunities for the advancement of medical research, the improvement of healthcare, and the enhancement of patient safety.
Issues
  • “A sustainable business model for using EHR data for research purposes in Europe is required“
  • Gaps exist due to:
    • the variety of existing (incomplete) technical solutions
    • regional diversity and individual approaches
    • the lack of a common viable business model across Europe
Project Outputs

The expected outputs of the project are:

  • Requirements specification
  • The EHR4CR Business Model
  • The EHR4CR Technical Platform (a set of tools and services)
  • Pilots for validating the solutions:
    • for different scenarios (e.g. protocol feasibility, patient recruitment,...);
    • across different therapeutic areas (e.g. oncology);
    • across several countries (under different legal frameworks).
Main EHR4CR Scenarios
  • Clinical protocol feasibility
  • Patient identification and recruitment
  • Clinical trial execution
  • Adverse event reporting
Disease Areas covered in Pilots
Diabetes
  • Provisional list:
  • Oncology
  • Inflammatory diseases
  • Neuroscience
  • Diabetes
  • Cardiovascular diseases
  • Respiratory diseases
EHR4CR Business model

The EHR4CR business model will:

    Business Model
  • Specify in detail the product and service offering;
  • Include analyses and an impact analysis on multiple stakeholders;
  • Deliver a self-sustaining economic model including sensitivity analysis;
  • Define appropriate governance arrangements for the platform services and for pan-European EHR4CR networks;
  • Define operating procedures and trusted third party service requirements;
  • Identify the value proposition and incentives for each of the key players and stakeholders impacted by EHR4CR;
  • Define accreditation and certification plans for EHR systems capable of interfacing with the platform;
  • Provide a framework to define public and private sector roles in reusing EHRs for clinical research;
  • Define a roadmap for pan-European adoption and for funding future developments.
EHR4CR Technical Platform

EHR4CR platform will:

    Platform Services
  • Support the feasibility, exploration, design and execution of clinical studies and long-term surveillance of patient populations;
  • Enable trial eligibility and recruitment criteria to be expressed in ways that permit searching for relevant patients across distributed EHR systems, and initiate confidentially participation requests via the patients’ authorised clinicians;
  • Provide harmonised access to multiple heterogeneous and distributed clinical (EHR) systems and integration with existing clinical trials infrastructure products (e.g. EDC systems);
  • Facilitate improvements of data quality to enable routine clinical data to contribute to clinical trials, and importantly vice versa, thereby reducing redundant data capture.
Benefits

SEALAccreditation of Clinical Research Units and Certification of EHR systems will accelerate the adoption of a more harmonised approach throughout Europe and serve as a powerful means for ensuring to the pharmaceutical industry the reliability and trustworthiness of the research partners (i.e. of the data providers, e.g. hospitals).

The EHR4CR approach will thus also enable research and clinical trials to be delivered more cost effectively.

Both vendors of certified products and hospitals (source data) that will be accredited will have a competitive advantage.

The EHR4CR business model for re-using EHR data in research aims at offering benefits for all stakeholders and strengthen the collaboration amongst all the partners in research.

 

Examples of benefits

Academic perspective:

  • Provide tools and services to better plan and conduct academic trials (investigator-initiated trials)
  • Facilitate comparative effectiveness research

Pharmaceutical perspective:

  • Improve speed and quality of the patient recruitment process and study design by accurate understanding of real patient populations
  • Support to conduct observational and outcomes research studies in real-world settings

General Healthcare perspective:

  • Significant facilitation of the re-use of EHR data to allow more efficient management of public health issues
  • Closer co-ordination between care providers and patients, resulting in safer and more evidence-based diagnosis and treatment
Socio-economic impact

EHR4CR represents a paradigm shift given the holistic and multi-disciplinary approach in the development of its Business Model with:

  • Benefits for the participating EFPIA companies and the entire pharmaceutical industry
  • Benefits for the IMI program (cf. the IMI JU key objectives)
  • Benefits for the hospital data providers, the EHR system vendors, the clinical researchers…
  • Benefits for the patients
EHR4CR concept overview
Concept overview
Project Objectives
Project objectives
Vision: Scalable Organisational Model for EHR re-use
Vision
Overview of Platform services
Overview platform services
EHR4CR data source flow
EHR4CR data source flow
Proposed End-point Split-up
Poposed End-point Split-up
PFS - Proposed Initial Approach

Agreed starting point for the Protocol Feasibility Scenario:

Prposed Initial Approach
Expected Impact
Expected Impact
KEY PROJECT DELIVARABLES
Download Executive summaries
17/12/2012
PROJECT NEWS
Posters - Flyers
05/11/2011
SUPPORTED BY

The EHR4CR project is partially funded by the IMI Programme.

imi

The Innovative Medicines Initiative (IMI) is a unique public-private partnership designed by the European Commission and European Federation of Pharmaceutical Industries and Associations (EFPIA). It is a pan-European collaboration that brings together large biopharmaceutical companies, small- and medium-sized enterprises (SMEs), patient organisations, academia, hospitals and public authorities.

Efpia  Europe

Executive Summary

Download here

[5 November 2011]

Bridging the gap

Price Waterhouse Cooper’s report on “Transforming Healthcare through Secondary Use of Health Data” (October, 2009)…one of the key messages:

What it means for your business?
“Industry stakeholders are calling for a framework to define public and private sector roles in secondary data use”

This is exactly what EHR4CR is all about

EFPIA RSS
LOGIN

IMI news
IMI news
More info

Cookies In Use on This Site

×
   

Cookies and how they Benefit You

Our website uses cookies, as almost all websites do, to help provide you with the best experience we can. Cookies are small text files that are placed on your computer or mobile phone when you browse websites

Our cookies help us:

  • Make our website work as you'd expect
  • Save you having to login every time you visit the site
  • Remember your settings during and between visits
  • Improve the speed/security of the site
  • Continuously improve our website for you

We do not use cookies to:

  • Collect any personally identifiable information (without your express permission)
  • Collect any sensitive information (without your express permission)
  • Pass data to advertising networks
  • Pass personally identifiable data to third parties
  • Pay sales commissions

You can learn more about all the cookies we use below

 

Granting us permission to use cookies

If the settings on your software that you are using to view this website (your browser) are adjusted to accept cookies we take this, and your continued use of our website, to mean that you are fine with this. Should you wish to remove or not use cookies from our site you can learn how to do this below, however doing so will likely mean that our site will not work as you would expect.

 

More about our Cookies

Website Function Cookies

Our own cookies

We use cookies to make our website work including:

  • Determining if you are logged in or not
  • Remembering your search settings
  • Remembering if we have already asked you certain questions (e.g. you declined to use our app or take our survey)

There is no way to prevent these cookies being set other than to not use our site.

Third party functions

Our site, like most websites, includes functionality provided by third parties. A common example is Google Analytics.

Disabling these cookies will likely break the functions offered by these third parties

Anonymous Visitor Statistics Cookies

We use cookies to compile visitor statistics such as how many people have visited our website, what type of technology they are using (e.g. Mac or Windows which helps to identify when our site isn't working as it should for particular technologies), how long they spend on the site, what page they look at etc. This helps us to continuously improve our website. These so called analytics� programs also tell us if , on an anonymous basis, how people reached this site (e.g. from a search engine) and whether they have been here before helping us to put more money into developing our services for you instead of marketing spend.

 

Turning Cookies Off

You can usually switch cookies off by adjusting your browser settings to stop it from accepting cookies (Learn how here). Doing so however will likely limit the functionality of our's and a large proportion of the world's websites as cookies are a standard part of most modern websites

It may be that you concerns around cookies relate to so called "spyware". Rather than switching off cookies in your browser you may find that anti-spyware software achieves the same objective by automatically deleting cookies considered to be invasive. Learn more about managing cookies with antispyware software.